{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:14:35Z","timestamp":1760573675082,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.prp.2025.156207","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T14:13:13Z","timestamp":1756649593000},"page":"156207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High-dose vitamin C improves BCG immunotherapy\u2019s efficacy in a murine ectopic model of bladder cancer"],"prefix":"10.1016","volume":"275","author":[{"given":"Roham","family":"Deyhimfar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keykavos","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman Menbari","family":"Oskouie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila Zareian","family":"Baghdadabad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Zahmatkesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Shoghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Mesbah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fateme","family":"Guitynavard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad Kazem","family":"Aghamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clinicians"},{"key":"10.1016\/j.prp.2025.156207_bib2","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.prp.2025.156207_bib3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prp.2025.156207_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.prp.2025.156207_bib6","first-page":"1315","article-title":"Internalization of mycobacterium bovis, bacillus calmette guerin, by bladder cancer cells is cytotoxic","volume":"18","author":"Pook","year":"2007","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.prp.2025.156207_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","article-title":"Requirement of a thymus dependent immune response for BCG-mediated antitumor activity","volume":"137","author":"Ratliff","year":"1987","journal-title":"J. Urol."},{"issue":"10","key":"10.1016\/j.prp.2025.156207_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat. Rev. Urol."},{"issue":"5","key":"10.1016\/j.prp.2025.156207_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eursup.2004.02.013","article-title":"Prognosis of T1G3 tumors: clinical factors","volume":"3","author":"Barmoshe","year":"2004","journal-title":"Eur. Urol. Suppl."},{"issue":"4","key":"10.1016\/j.prp.2025.156207_bib12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0022-5347(17)36197-9","article-title":"Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule","volume":"149","author":"Melekos","year":"1993","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"National bacillus Calmette-Guerin\/Interferon phase 2 investigator G. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O\u2019Donnell","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.prp.2025.156207_bib14","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette\u2013Gu\u00e9rin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","author":"Wang","year":"2018","journal-title":"OncoTargets Ther."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbcan.2012.06.003","article-title":"Ascorbic acid: chemistry, biology and the treatment of cancer","volume":"1826","author":"Du","year":"2012","journal-title":"Biochimica et Biophysica Acta (BBA) Reviews Cancer"},{"key":"10.1016\/j.prp.2025.156207_bib16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3389\/fonc.2020.01483","article-title":"Mechanisms and applications of the anti-cancer effect of pharmacological ascorbic acid in cervical cancer cells","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0304-3835(96)04212-7","article-title":"Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro","volume":"103","author":"Kurbacher","year":"1996","journal-title":"Cancer Lett."},{"issue":"6266","key":"10.1016\/j.prp.2025.156207_bib18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1126\/science.aaa5004","article-title":"Vitamin c selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH","volume":"350","author":"Yun","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.prp.2025.156207_bib19","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.2147\/OTT.S222702","article-title":"High-dose vitamin c suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition","author":"Zeng","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5483\/BMBRep.2011.44.3.211","article-title":"Vitamin c increases the apoptosis via up-regulation p53 during cisplatin treatment in human colon cancer cells","volume":"44","author":"An","year":"2011","journal-title":"BMB Rep."},{"issue":"532","key":"10.1016\/j.prp.2025.156207_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8707","article-title":"High-dose vitamin c enhances cancer immunotherapy","volume":"12","author":"Magr\u00ec","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.prp.2025.156207_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1042\/BST20180169","article-title":"Vitamin C and immune cell function in inflammation and cancer","volume":"46","author":"Ang","year":"2018","journal-title":"Biochem. Soc. Trans."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ymthe.2021.09.015","article-title":"High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment","volume":"30","author":"Ma","year":"2022","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cam4.379","article-title":"Sex differences in bladder cancer pathology and survival: analysis of a population-based cancer registry","volume":"4","author":"Zaitsu","year":"2015","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.prp.2025.156207_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.5306\/wjco.v12.i9.712","article-title":"Embracing cancer immunotherapy with vital micronutrients","volume":"12","author":"Yuen","year":"2021","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156207_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-5347(17)34863-2","article-title":"Megadose vitamins in bladder cancer: a double-blind clinical trial","volume":"151","author":"Lamm","year":"1994","journal-title":"J. Urol."},{"key":"10.1016\/j.prp.2025.156207_bib27","first-page":"284","article-title":"NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation","volume":"6","author":"Garc\u00eda-Cuesta","year":"2015","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.prp.2025.156207_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2025.156207_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155997","article-title":"Infiltrating natural killer cells influence the efficacy of BCG immunotherapy in non-muscle-invasive bladder cancer","volume":"270","author":"Lima","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"9","key":"10.1016\/j.prp.2025.156207_bib30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.imbio.2011.12.010","article-title":"Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model","volume":"217","author":"Kim","year":"2012","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/08923979709046977","article-title":"Enhancement of natural killer cell activity and t and b cell function by buffered vitamin c in patients exposed to toxic chemicals: the role of protein kinase-C","volume":"19","author":"Heuser","year":"1997","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.prp.2025.156207_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154739","article-title":"Tumor-associated macrophages: potential therapeutic targets and diagnostic markers in cancer","volume":"249","author":"Song","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.prp.2025.156207_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95157-6","article-title":"MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model","volume":"11","author":"de Queiroz","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2025.156207_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-32-87","article-title":"Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer","volume":"32","author":"Suriano","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.prp.2025.156207_bib35","doi-asserted-by":"crossref","first-page":"17389","DOI":"10.1021\/acsnano.2c08446","article-title":"Polarization of tumor-associated macrophages promoted by vitamin C-loaded liposomes for cancer immunotherapy","volume":"16","author":"Ma","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.prp.2025.156207_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J. Urol."},{"issue":"15","key":"10.1016\/j.prp.2025.156207_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu1727","article-title":"Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma","volume":"11","author":"Mou","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.prp.2025.156207_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156081","article-title":"T cell exhaustion: focus on molecular pathways","author":"Dang","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156207_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154711","article-title":"Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in cancer","volume":"248","author":"Li","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.prp.2025.156207_bib41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory t cells are enriched during BCG therapy and May limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2005.05.004","article-title":"BCG dose reduction by decreasing the instillation frequency: effects on local Th1\/Th2 cytokine responses in a mouse model","volume":"48","author":"de Boer","year":"2005","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-5347(01)67113-1","article-title":"Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy","volume":"154","author":"Esuvaranathan","year":"1995","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.prp.2025.156207_bib44","first-page":"179","article-title":"Production of IL-5, a classical t (H) 2 cytokine, following bacillus calmette guerin immunotherapy of bladder cancer","volume":"9","author":"Alexandroff","year":"1996","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/08923970903300151","article-title":"Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre-and post-intravesical combination immunotherapy","volume":"32","author":"Agarwal","year":"2010","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"4","key":"10.1016\/j.prp.2025.156207_bib46","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-\u03b1 2B enhances Th1 cytokine responses in bladder cancer patients receiving mycobacterium bovis bacillus Calmette-Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J. Immunol."},{"issue":"21","key":"10.1016\/j.prp.2025.156207_bib47","doi-asserted-by":"crossref","first-page":"10471","DOI":"10.1021\/jf902403p","article-title":"High dose vitamin c supplementation increases the Th1\/Th2 cytokine secretion ratio, but decreases eosinophilic infiltration in bronchoalveolar lavage fluid of ovalbumin-sensitized and challenged mice","volume":"57","author":"Chang","year":"2009","journal-title":"J. Agric. Food Chem."},{"issue":"10","key":"10.1016\/j.prp.2025.156207_bib48","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1002\/jsfa.13419","article-title":"Anti-allergic effect of vitamin c through inhibiting degranulation and regulating TH1\/TH2 cell polarization","volume":"104","author":"Li","year":"2024","journal-title":"J. Sci. Food Agric."},{"key":"10.1016\/j.prp.2025.156207_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-9966-27-78","article-title":"Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model","volume":"27","author":"Chade","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.2010.04105.x","article-title":"Interleukin-10 inhibits mycobacterium bovis bacillus Calmette\u2013Gu\u00e9rin (BCG)-induced macrophage cytotoxicity against bladder cancer cells","volume":"160","author":"Luo","year":"2010","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.156207_bib51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cei.12315","article-title":"Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette\u2013Gu\u00e9rin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity","volume":"177","author":"Newton","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2025.156207_bib52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.niox.2012.07.001","article-title":"Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer","volume":"27","author":"Koskela","year":"2012","journal-title":"Nitric Oxide"},{"issue":"4","key":"10.1016\/j.prp.2025.156207_bib53","first-page":"565","article-title":"Inhibition of bacillus Calmette-Guerin-induced nitric oxide in bladder tumor cells May improve BCG treatment","volume":"16","author":"Alvarez","year":"2005","journal-title":"Int. J. Mol. Med."},{"issue":"4","key":"10.1016\/j.prp.2025.156207_bib54","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00356.2016","article-title":"Doxorubicin-induced nitrosative stress is mitigated by vitamin c via the modulation of nitric oxide synthases","volume":"312","author":"Akolkar","year":"2017","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.prp.2025.156207_bib55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2025.156207_bib56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3892\/or.2015.3985","article-title":"Recombinant hIFN-\u03b12b-BCG inhibits tumor growth in a mouse model of bladder cancer","volume":"34","author":"Sun","year":"2015","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.prp.2025.156207_bib57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cellimm.2010.10.005","article-title":"Vitamin C-treated murine bone marrow-derived dendritic cells preferentially drive na\u00efve t cells into Th1 cells by increased IL-12 secretions","volume":"266","author":"Jeong","year":"2011","journal-title":"Cell. Immunol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825004005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:34:26Z","timestamp":1760502866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825004005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":57,"alternative-id":["S0344033825004005"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156207","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose vitamin C improves BCG immunotherapy\u2019s efficacy in a murine ectopic model of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156207"}}